Key result
Heterozygous MYBPC3 truncation mutation mice showed decreased maximal force development and reduced E/A ratios compared to wild-type littermates.
Why the study?
Does a heterozygous MYBPC3 truncation mutation cause functional impairments in mice before the onset of overt hypertrophy?
Does a heterozygous MYBPC3 truncation mutation cause functional impairments in mice before the onset of overt hypertrophy?
Seemingly asymptomatic heterozygous MYBPC3 carriers exhibit subtle contractile and diastolic impairments that precede overt hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Subtle myofilament and diastolic deficits precede hypertrophy in asymptomatic MYBPC3 mice; leaves open early detection or intervention in human carriers.
The etiology of hypertrophic cardiomyopathy (HCM) has been ascribed to mutations in genes encoding sarcomere proteins. In particular, mutations in MYBPC3, a gene which encodes cardiac myosin binding protein-C (cMyBP-C), have been implicated in over one third of HCM cases. Of these mutations, 70% are predicted to result in C'-truncated protein products, which are undetectable in tissue samples. Heterozygous carriers of these truncation mutations exhibit varying penetrance of HCM, with symptoms often occurring later in life. We hypothesize that heterozygous carriers of MYBPC3 mutations, while seemingly asymptomatic, have subtle functional impairments that precede the development of overt HCM. This study compared heterozygous (+/t) knock-in MYBPC3 truncation mutation mice with wild-type (+/+) littermates to determine whether functional alterations occur at the whole-heart or single-cell level before the onset of hypertrophy. The +/t mice show ∼40% reduction in MYBPC3 transcription, but no changes in cMyBP-C level, phosphorylation status, or cardiac morphology. Nonetheless, +/t mice show significantly decreased maximal force development at sarcomere lengths of 1.9 μm (+/t 68.5 ± 4.1 mN/mm(2) vs. +/+ 82.2 ± 3.2) and 2.3 μm (+/t 79.2 ± 3.1 mN/mm(2) vs. +/+ 95.5 ± 2.4). In addition, heterozygous mice show significant reductions in vivo in the early/after (E/A) (+/t 1.74 ± 0.12 vs. +/+ 2.58 ± 0.43) and E'/A' (+/t 1.18 ± 0.05 vs. +/+ 1.52 ± 0.15) ratios, indicating diastolic dysfunction. These results suggest that seemingly asymptomatic heterozygous MYBPC3 carriers do suffer impairments that may presage the onset of HCM.
No takes yet. Share an insight, caveat, or question.
Barefield et al. (2014) studied Hypertrophic cardiomyopathy. Heterozygous MYBPC3 truncation mutation vs. Wild-type (+/+) littermates was evaluated on Maximal force development at sarcomere length of 1.9 μm (mN/mm2). Heterozygous MYBPC3 truncation mutation mice showed decreased maximal force development and reduced E/A ratios compared to wild-type littermates.
Synapse has enriched 10 related papers. Consider them for comparative context: